OR WAIT 15 SECS
ValiRx entered into a collaboration agreement with the Deutsches Krebsforschungzentrum cancer research center.
ValiRx, a life-science company with a focus on cancer diagnostics and therapeutics for personalized medicine, entered into a collaboration agreement with the Deutsches Krebsforschungzentrum (DKFZ), a German cancer research center, for the further development of ValiRx’s proprietary Gene Inactivation through Chromatin Engineering (GeneICE) technology platform. The goal of the research is to develop new targeting technologies that will improve the early detection and diagnosis of various cancers and new GeneICE compounds aimed at enhancing treatment outcomes.
The agreement builds on the ValiRx-DKFZ association announced in August 2013 by expanding the scope of the research to cover a wider range of activities relating to the development of the GeneICE technology and its use in the treatment of cancer, as well as its diagnostic and research applications. The agreement is aimed at accelerating the translation of the preclinical evidence supporting the GeneICE technology’s potential to silence specific "rebellious genes" implicated in causing cancers, and take individualized cancer medicine from bench to bedside.